Eli Lilly and Company

Lance Allen Pfeifer

Bryan Hurst Norman

Timothy Ivo Richardson

Maria Carmen Fernandez

Maria Rosario Gonzalez-Garcia

Spencer Brian Jones

Jeffrey A Dodge

Charles Willis Lugar, Iii

Nathan Bryan Mantlo

Tianwei Ma

Thomas John Bleisch

Thomas James Beauchamp

Blake L Neubauer

Venkatesh Krishnan

Douglas Linn Gernert

Bin Liu

Ashraf Saeed

Gregory Lee Durst

Robert Anthony Doti

Yen Dao

Antonio Navarro

The present invention provides compounds of the formula (I) or a pharmaceutically acceptable salt thereof. Compounds of the invention are autotaxin inhibitors useful in the treatment of pain associated with osteoarthritis. 

Dihydropyrido pyrimidine compounds as autotaxin inhibitors

The present invention provides compounds of the formula I, wherein X is a bond or CH; Q is CHor O; L is selected from the group consisting of &#x2014;OCH&#x2014; and &#x2014;CHO&#x2014;; or a pharmaceutically acceptable salt thereof. Compounds of the invention are autotaxin inhibitors. 

Imidazo pyridine compounds

The present invention provides compounds of Formula I or a pharmaceutical salt thereof, where the variables for R1, R2, and R3 are as described herein; methods of treating a condition such as hypertriglyceridemia; and processes for preparing the compounds. 

Phenyl methanesulfonamide derivatives useful as MGAT-2 inhibitors

The present invention provides compounds of the Formula I:   Compounds of this invention are autotaxin inhibitors.

Bicyclic pyrimidine compounds

The present invention provides compounds of Formula below: and analogues thereof where the various substituent groups, R1, R2, R3, R4, R5 A, and X are described herein; or a pharmaceutical salt thereof; a method of treating a condition such as hypertriglyceridemia and a process for preparing the compounds.

Benzyl sulfonamide derivatives useful as MOGAT-2 inhibitors

The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof useful as Estrogen Receptor beta agonists for treating Estrogen Receptor beta mediated diseases such as benign prostatic hyperplasia.

Substituted benzopyrans as selective estrogen receptor-beta agonists

The present invention is directed to compounds represented by the following structural formula, Formula (I): wherein: (a) X is selected from the group consisting of a single bond, O, S, S(O)and N; (b) U is an aliphatic linker; (c) Y is selected from the group consisting of O, C, S, NH and a single bond; (d) W is N, O or S; (e) E is C(R3)(R4)A or A and wherein; (f) A is selected from the group consisting of carboxyl, tetrazole, C-Calkylnitrile, carboxamide, sulfonamide and acylsufonamide. The other substituents are defined in the claims; the compounds are modulators of peroxisome proleferator activated receptors (PPARs) and are useful for the treatment of diabetes and other metabolic disorders.

Triazole PPAR modulators

The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof and processes for the preparation of the same. The compounds of the present invention are useful as Estrogen Receptor ? agonists. Such agonists are useful for the treating Estrogen Receptor ? mediated diseases such as prostate cancer or BPH.

The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof and processes for the preparation of the same. The compounds of the present invention are useful as Estrogen Receptor &#x3b2; agonists. Such agonists are useful for the treating Estrogen Receptor &#x3b2; mediated diseases such as prostate cancer.

Growing community of inventors

Carmel, IN, United States of America

Lance Allen Pfeifer